Abstract:Aim: DNAs containing unmethylated CpG motifs can stimulate innate and adaptive immunity. The aim of this study was to investigate the immunostimulatory and anti-neoplasm effects of a novel CpG oligodeoxynucleotide, ODN10, in tumor-bearing mice. Methods: B16 melanoma-bearing C57BL/6 mice were administered ip or sc with ODN10 or conventional CpG ODN1826 on the indicated days post inoculation. The animal survival rate and the inhibitory effect on tumor growth were observed in vivo . B and T lymphocyte proliferation, natural killing cell cytotoxicity and the phagocytic ability of peritoneal macrophages from the animals were determined using [ 3 H]-thymidine incorporation assay, 4-h 51 Cr release assay and neutral red chromometry method, respectively. The serum levels of IL-12, IL-4 and IgE were quantified using ELISA assays. Histological examination of tumor tissues was performed after HE staining, and the expression of PCNA, CD63, and CD80 in tumor tissues was analyzed with immunohistochemistry. Results: ODN10 (1, 5 and 25 mg/kg) significantly inhibited the growth and metastasis of the tumor, and significantly prolonged the survival of tumor-bearing mice, as compared with ODN1826. The immune status was suppressed in tumor-bearing mice. Both ODN10 and ODN1826 significantly reversed the suppressed immunoactivities in tumor-bearing mice, which included promoting B and T lymphocyte proliferation, enhancing NK cell and peritoneal macrophage activities, inducing IL-12 secretion and inhibiting IL-4 and IgE secretion. Further, CpG ODNs decreased PCNA and CD63 expression while induced expression of CD80. ODN10 presented more potent activity, and displayed the most prominent immunostimulatory potential. Conclusion: ODN10 produces prominent immunomodulatory effects on cellular immunity in tumor-bearing mice, which might help reverse the established Th2-type responses to the Th1-type responses, thus may be used as a potent anti-tumor immunotherapy agent or adjuvant.

Research Progress on Anti-Tumor and Immunity Activity of CpG

Research Progress of CpG-DNA Adjvants

The Relation Between the Specific Structure and Immunostimulatory Function of CpG-DNA

CpG Oligodeoxynucleotides Enhance the Efficacy of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes by Modifying the Th1 Polarization and Local Infiltration of Th17 Cells

Adcances in CpG oligodeoxynucleotides in the cancer immunotherapy

Anti-neoplasm and immuno-modification effect of novel CpG oligodeoxynucleotides in mice

CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials

Antitumor Activity Mediated By Cpg: The Route Of Administration Is Critical

Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics.

Immunostimulatory and Anti-Neoplasm Effects of a Novel Palindrome CpG Oligodeoxynucleotide in Mice

CpG-PEG Conjugates and Their Immune Modulating Effects after Systemic Administration

Dddt_a_325790 3953..3963

Advances in research on the treatment of non-small-cell lung cancer by unmethylated cytidine-phosphate-guanosine-containing oligodeoxynucleotides（CpG ODN）

Enhanced Immunostimulatory Activity of a Cytosine-Phosphate-Guanosine Immunomodulator by the Assembly of Polymer DNA Wires and Spheres

Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade

Enhancing Immunogenicity by CpG DNA.

Effects of CpG ODN on Dendritic Cells and Its Mechanisms

Potent Anti-Tumor Immunostimulatory Biocompatible Nanohydrogel Made from DNA

Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy

Cpg Oligodeoxynucleotide Developed To Activate Primate Immune Responses Promotes Antitumoral Effects In Combination With A Neoantigen-Based Mrna Cancer Vaccine

Signal Transduction and Negative Regulation Activated by CpG DNA